AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca PLC (LSE:AZN)'s first-quarter results were thoroughly welcomed by the market. So much so, that its market valuation has surpassed oil major Shell to become Britain's most valuation corporation.

AstraZeneca is now Britain's top stock- can it move higher?

ROCKVILLE, Md. , April 25, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31 to June 4, 2024.

AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

AstraZeneca plc today, on April 25, announced its earnings report for the first quarter of FY24. Total Revenue increased by 19% to $ 12,679 million, driven by an 18% increase in product sales and continued growth in Alliance Revenue from partnered medicines.

AstraZeneca earnings beat expectations as steady drug sales boost revenues

Bristol-Myers

Sanofi

AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.

AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags

AstraZeneca PLC (LSE:AZN)'s solid rally following Thursday's first-quarter earnings print has made the pharmaceuticals giant Britain's most valuable company, overtaking oil major Shell. AstraZeneca posted a robust set of financial results that sent its share price over 6% higher, meaning its valuation has increased by a quarter since mid-February.

AstraZeneca overtakes Shell as Britain's most valuable company.

AstraZeneca reiterated its full-year guidance after posting first-quarter core earnings and sales above forecasts.

AstraZeneca Earnings, Sales Beat Views

Britain's leading pharmaceuticals company AstraZeneca hit the mark in today's first-quarter earnings print. Total revenue increased by 19% at constant exchange rates to $12.7 billion (£10.2 billion), driven by an 18% increase in product sales.

AstraZeneca ticks the boxes in first quarter

AstraZeneca reported quarterly revenue and profit above market estimates on Thursday, buoyed by resilient demand for its oncology and rare blood disorder drugs.

AstraZeneca beats first-quarter revenue, profit estimates

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Q1 Earnings Release (25 April 2024).

AstraZeneca --- Q1 2024 results

Rolls-Royce Holdings PLC

Unilever

The Magnificent 7 will be hogging US financial news headlines over the coming weeks. Not to be confused with the Yul Byrnner-starring 60s Western classic, the term refers to the seven premier Big Tech stocks on the Nasdaq 100, namely Alphabet, Amazon, Apple, Meta Platforms, Microsoft, NVIDIA and Tesla.

Britain's Magnificent 7: Do Rolls-Royce, AstraZeneca and Unilever make the cut?

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) shares jumped 30% following the announcement of a strategic partnership with AstraZeneca PLC (LSE:AZN) that aims to advance cancer drug development by enhancing the former's DNA damage response assay. Specifically, the collaboration will focus on adapting ANGLE's existing Parsortix-based assay for identifying micronuclei in circulating tumour cells (CTCs), a crucial step in studying DNA damage responses.

ANGLE shares jump 30% on AstraZeneca tie-up

AstraZeneca's stock has declined by nearly 8% over the past year due to slowing sales of its COVID-19 vaccine.

AstraZeneca: What The Market's Missing

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of liquid biopsy technologies, has partnered with AstraZeneca PLC (LSE:AZN) to enhance cancer drug development by 'leveraging' the former's DNA damage response assay. Specifically, the collaboration will focus on adapting ANGLE's existing Parsortix-based assay for identifying micronuclei in circulating tumour cells (CTCs), a crucial step in studying DNA damage responses.

ANGLE inks AstraZeneca deal to develop ground-breaking cancer assay

Merck

Pfizer

Big money tends to flow from one sector to the other. During the pandemic, sectors like pharmaceutical and e-commerce were hot.

3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect

Beyond analysts' top -and-bottom-line estimates for Astrazeneca (AZN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics

Barrick Gold

Lockheed Martin

Inflation in the United States has been stubborn and a matter of concern for policymakers. For March, the consumer price increase rose by 3.5% on a year-on-year basis, which was more than expected.

3 Blue-Chip Stocks to Buy as High Inflation Persists

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes?

Astrazeneca (AZN) Could Be a Great Choice

Amgen

Structure Therapeutics Inc

Eli Lilly

Novo Nordisk

Viking Therapeutics

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million. The financing was led by RA Capital Management, and included new investors AstraZeneca (LSE/STO/Nasdaq: AZN) and Bristol Myers Squibb, along with existing investors Janus Henderson Investors, Third Rock Ventures, Wellington Manageme.

Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials

WILMINGTON, Del.--(BUSINESS WIRE)--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC). These results from TOPAZ-1, which are the longest survival follow-up ever reported for a global, randomized Phase III trial in this setting, will be presented on A.

IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

AstraZeneca PLC (LSE:AZN) has been upgraded by a leading investment bank following guidance on the company's dividend policy, and a more positive earnings outlook. Deutsche Bank has moved to 'hold' from 'sell' on stock in the pharma giant as well as raising its price target by 1,00p to 10,500p.

AstraZeneca upgrade (of sorts) by leading investment bank

The future of the U.S. economy appears promising, with robust growth and strong corporate performance. This economic strength has propelled the stock market to record highs, signaling confidence in the economy's resilience.

3 Pharma Stocks That Are Money-Printing Machines in 2024

AstraZeneca PLC (LSE:AZN) is poised to maintain its full-year financial guidance without adjustments when it announces its first-quarter results later this month (April 25), according to insights from Shore Capital, which expects any significant updates to be unveiled at the drugs giant's capital markets day on May 21. The company's cancer drugs, Imfinzi and Imjudo, are expected to show a robust performance, despite mandatory price cuts in Japan affecting the former.

AstraZeneca: A case of steady-as-she-goes, says broker

BAE Systems PLC

British American Tobacco

Diageo

Legal & General Group PLC

National Grid

RELX

Smith & Nephew

The list ranks stocks based on their market cap and dividend yield alone. What I am looking for is quality dividend stocks with long track records of progressive dividend growth, and while dividend yield is still important, it's a secondary consideration.

U.K. Top 40 Quality Dividend Stocks: Q2 2024

News for AstraZeneca Stock (AZN)